Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20811159&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Therapeutic targets in age-related macular disease Bird ACJ Clin Invest 2010[Sep]; 120 (9): 3033-41Age-related macular disease (AMD) accounts for more than 50% of blind registration in Western society. Patients with AMD are classified as having early disease, in which visual function is well preserved, or late disease, in which central vision is lost. Until recently, there was no therapy available by which the course of the disorder could be modified. Now, the most common form of late-stage AMD - choroidal neovascularization - responds to treatment with anti-VEGF therapies; although visual loss is modified in a portion of these cases, no therapeutic approach exists that alters the evolution from early to late disease. However, as discussed in this Review, research over the last few years has demonstrated several features of AMD that are likely to be amenable to treatment. Potential targets for treatment are described, and possible therapeutic approaches are discussed.|*Aging[MESH]|Angiogenesis Inhibitors/therapeutic use[MESH]|Animals[MESH]|Blindness/drug therapy[MESH]|Choroidal Neovascularization/*drug therapy[MESH]|Disease Models, Animal[MESH]|Eye/anatomy & histology/pathology/ultrastructure[MESH]|Humans[MESH]|Macular Degeneration/classification/*drug therapy/therapy[MESH]|Mice[MESH]|Mice, Knockout[MESH]|Rats[MESH]|Rats, Sprague-Dawley[MESH]|Research/trends[MESH]|Vascular Endothelial Growth Factor A/antagonists & inhibitors/therapeutic use[MESH] |
